Feasibility and Diagnostic Value of Recording Smartwatch Electrocardiograms in Neonates and Children
Leroux et al.
The finding, in our words
Smartwatch single-lead ECG recordings from 110 children aged one week to 16 years demonstrated 84% sensitivity and 100% specificity for detecting electrocardiographic abnormalities against 12-lead ECG reference. While 99% of tracings were analysable, 14% of abnormalities were missed, mainly due to artefact. Rhythm disorders and bundle branch blocks were detected reliably, indicating potential for remote cardiac screening in paediatric patients.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Across perinatal care, wearable sensors and home-monitoring platforms support timely intervention, with remote monitoring linked to a 7 to 11 percent reduction in maternal mortality and preeclampsia incidence. In neonatal care, predictive digital monitoring such as the Heart Rate Observation system reduced mortality in very low-birth-weight infants by approximately 20 percent.
This systematic review of ten studies with 49,172 participants found that machine-learning models integrating continuous glucose monitoring data with clinical, genetic and multi-omic biomarkers achieved AUC values up to 0.993 for early type 1 diabetes detection, with plasma CXCL10 and IL-1RA emerging as useful markers. The findings support decentralised diagnostics by validating wearable-derived digital biomarkers alongside plasma biomarkers, though data heterogeneity and limited generalisability remain barriers to clinical implementation.
Mittal et al., International journal of molecular sciences · source ↗
The study observed favourable trends in the accrual of participants residing far from the site and those from underrepresented groups following the implementation of a decentralised clinical trial program.
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.
A fully remote decentralised clinical trial in Danish adults with type 2 diabetes demonstrated operational feasibility with rapid recruitment, high retention (87 percent), and excellent adherence to continuous glucose monitoring (95 percent achieving ≥70 percent data coverage) and telemedicine visits (97 percent). Activity tracker adherence was poor (12 percent) due to technical issues, but remote safety monitoring was effective with no unexpected adverse events, supporting the viability of remote diabetes management.